Brought to you by 
Series A round brings $25mm to Kyverna
16 Jan 2020
Executive Summary
| Kyverna Therapeutics raised $25mm through its Series A round from investors including Vida Ventures, Westlake Village BioPartners, and Gilead Sciences. The company was formed in 2018 and is developing treatments for serious autoimmune diseases based on its T-cell engineering and synthetic biology technologies. Concurrent with the Series A, Kyverna also announced a new deal with Gilead under which Kyverna will use its platforms to discover and develop T-cell therapies, to which Gilead will hold licensing options. |
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A round brings $25mm to Kyverna
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice